兰州大学机构库 >学院待认领
利那洛肽应用于C-IBS的疗效及安全性的META分析
Alternative TitleThe effective and safety of Linaclotide on constipation predominant irritable bowel syndrome: A Meta-analysis
黄显斌
Thesis Advisor郭天康
2015-05-20
Degree Grantor兰州大学
Place of Conferral兰州
Degree Name硕士
Keyword利那洛肽 便秘型肠易激综合征 安慰剂 随机对照试验 Meta分析
Abstract目的: 评价利那洛肽与安慰剂对比在便秘型肠易激综合征(C-IBS: constipation predominant irritable bowel syndrome)患者中的疗效及安全性. 方法: 中国期刊全文数据库(China National Knowledge Internet, CNKI), 中国生物医学文献数据库(China Biology Medicine, CBM),中国万方数据库,中国维普数据库, PubMed, Embase, Web of science, the Cochrane library和clinical trials.gov等数据库中关于利那洛肽应用于成人C-IBS的与安慰剂对照的随机对照试验. 结果用stata 13.0和RevMan v5.2版本统计了相对危险因素(relative risk, RR)和95%可信区间(confidence intervals, 95%CI)等二分类资料. 结果: 检索出符合要求的关于利那洛肽用于C-IBS的5个随机对照试验的4篇公开发表的文章. 主要观察指标为:腹痛的效果(RR=1.581, 95%CI=1.018,2.456);对完全性自发排便(complete spontaneous bowel movements, CSBMs)的改善(RR=3.213,95%CI= 2.412,4.280);腹胀的效果(RR=1.535, 95%CI=1.132,2.081);大便粘稠度的改善(RR=1.323,95%CI=1.243,1.408);患者生活质量的改善(RR=1.297,95%CI= 1.060,1.588).与安慰剂相比,腹泻是利那洛肽最常发生的不良反应. 结论: 通过本研究比较得知, 利那洛肽与安慰剂相比, 能改善肠道功能, 减轻腹痛症状和改善C-IBS患者的生活质量.
Other AbstractAIM: To perform a meta-analysis to determine the efficacy and the safety of linaclotide, compared with placebo, for patients with constipation predominant irritable bowel syndrome (C-IBS). METHODS: CNKI, CBM, wanfang, VIP, PubMed, EMBASE, clinical trials.gov and the Cochrane library were searched for randomized, placebo controlled trials examining the effect of linaclotide in adults with C-IBS. Dichotomous results were pooled by using the software of stata 13.0 and RevMan v.5.2 to yield a relative risk (RR), 95% confidence intervals (CIs).RESULTS: The search identified five randomized controlled trials of linaclotide in patients with C-IBS published in four papers. The primary end point were: the RR (95%CI) of the responder of worst abdominal pains (RR = 1.581, 95%CI = 1.018,2.456); the responder of complete spontaneous bowel movements (CSBMs) (RR=3.213,95%CI= 2.412,4.280); the responder of abdominal bloating (RR=1.535, 95%CI=1.132,2.081); the responder of stool consistency(RR=1.323,95%CI=1.243,1.408); the responder of IBS Quality-of-life (RR = 1.38, 95%CI = 1.09-1.74). Diarrhea was the most frequently adverse event (AE) in the group of linaclotide than placebo.CONCLUSION: On the basis of our study, linaclotide improves bowel function and reduces abdominal pain and the quality-of-life of C-IBS, compared with placebo.
URL查看原文
Language中文
Document Type学位论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/223073
Collection学院待认领
Affiliation临床医学院
Recommended Citation
GB/T 7714
黄显斌. 利那洛肽应用于C-IBS的疗效及安全性的META分析[D]. 兰州. 兰州大学,2015.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[黄显斌]'s Articles
Baidu academic
Similar articles in Baidu academic
[黄显斌]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[黄显斌]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.